波音游戏-波音娱乐城赌球打不开

Recent advances in the synthesis, stability, and activation of platinum(IV) anticancer prodrugs
20210518_1.jpeg

Published on Angewandte Chemie (18 May 2021)

 

Author(s): Zoufeng Xu, Zhigang Wang, Zhiqin Deng, Guangyu Zhu*

 

Abstract

Platinum-based anticancer drugs have been widely applied in clinical settings for more than 40 years. The remarkable breakthroughs that have come from the use of these complexes in cancer therapy have stimulated a continual search for new platinum anticancer drugs. The most promising result of these efforts is a prodrug strategy based on the use of platinum(IV) versions of the traditional platinum(II) anticancer drugs. Hence, the design of synthetic methods for platinum(IV) prodrugs and an understanding of their hydrolytic stability and intracellular activation processes are critical for the development of platinum(IV) prodrugs for cancer therapy. In this review, we summarize recent progress in this field from a comprehensive viewpoint, with an emphasis first on the oxidation processes in chemical environments where platinum(II) compounds are converted to their platinum(IV) species, followed by the reduction processes in biological environments where platinum(IV) species are converted back to platinum(II) forms. First, recent approaches that use new oxidizing reagents to synthesize platinum(IV) prodrugs are summarized, and the oxidation mechanisms and outer-sphere functionalization of platinum(IV) prodrugs are examined. Second, the hydrolysis of platinum(IV) complexes, which has sometimes been underexplored, is discussed, and the factors associated with the hydrolytic stability of platinum(IV) complexes are reviewed. Last, we focus on the reduction of platinum(IV) prodrugs, from the perspectives of reduction potential, rate of reduction, reducing agents, and reduction products. The need for new strategies to achieve controllable intracellular reduction of platinum(IV) prodrugs is emphasized. This review aims to help researchers to improve their understanding of platinum(IV) anticancer prodrugs and hopefully to generate new ideas, strategies, and applications in the area of metal-based drugs.

 

20210518_2.jpeg


Read more: https://doi.org/10.1016/j.ccr.2021.213991

 

 

background
 
 
 
 
 
 
 
 
大发888登陆| 大发888出纳柜台 2014| 百家乐清零| 海立方娱乐城| 百家乐线上代理网站| 百家乐官网数据程序| 百家乐优博娱乐城| 百家乐官网游戏开发技术| 澳门百家乐职业| 百家乐官网闲庄和| 十六浦娱乐城信誉| 百家乐娱乐真人娱乐| 网络百家乐官网免费试玩| 大发888娱乐城积分| 百家乐有电脑游戏吗| 百家乐官网赌场赌场网站| 机率游戏| 在线百家乐电脑| 澳门百家乐官网赌场娱乐网规则| 来凤县| 大发888官网 df888| 澳门百家乐游戏说明书| 百家乐官网试玩1000元| 百家乐官网娱乐城地址| 必博备用网址| 现金网注册送彩金| 在线玩百家乐的玩法技巧和规则 | 大发888 dafa888 gzsums| 百家乐人生信条漫谈| 乐天堂百家乐官网娱乐平台| 大发888线上娱乐城加盟合作| 百家乐陷阱| 乐宝百家乐官网游戏| 德州扑克在线| 摩纳哥百家乐的玩法技巧和规则| 百家乐视频游戏会员| 豪华百家乐官网人桌| 百家乐官网连线游戏下载| 大发888游戏平台稳定大发888| 百家乐筹码套装包邮| 百家乐破解的办法|